Invasive ductal carcinoma of no special type and its corresponding lymph node metastasis: Do they have the same immunophenotypic profile?

Polish Journal of Pathology

Volumn 66, Issue 1, 2015, Pages 30-37

  Fulga, Veaceslav ^a   Rudico, Lucian ^a   Balica, Amalia Raluca ^b   Cimpean, Anca Maria ^b   Saptefrati, Lilian ^a   Raica, Marius ^b  

^a STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Breast cancer; Metastasis; Surrogate markers

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BIOPSY; BREAST TUMOR; CANCER STAGING; CELL DIFFERENTIATION; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PHENOTYPE; RETROSPECTIVE STUDY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84929431521     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/pjp.2015.51150     Document Type: Article

References (29)

1. American Cancer Society. Global Cancer Facts & Figures. 2nd Edition, Atlanta 2011
2. Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol 2009; 19: 204-210
3. Zaha DC, Lazăr E, Lăzureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol 2010; 51: 85-89
4. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752
5. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23
6. Hao X, Sun B, Hu L, et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004; 100: 1110-1122
7. Suzuki M, Tarin D. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: Clinical implications. Mol Oncol 2007; 1: 172-180
8. Falck AK, Fernö M, Bendahl PO, et al. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg 2010; 34: 1434-1441
9. Falck AK, Ferno M, Bendahl PO, et al. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases – aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer 2013; 13: 558
10. Falck AK, Bendahl PO, Chebil G, et al. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow- up. Breast Cancer Res Treat 2013; 140: 93-104
11. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2011; 22: 1736-1747
12. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168
13. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013; 31: 3997-4013
14. Azoulay S, Laé M, Fréneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 2005; 18: 1623-1631
15. Suciu C, Muresan AM, Cornea R, et al. Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast. Oncol Lett 2014; 7: 107-114
16. Weigelt B., Glas AM, Lodewyk F, et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003; 100: 15901-15905
17. van der Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002; 347: 1999-2009
18. Bernards R, Weinberg RA A progression puzzle. Nature 2002; 418: 823
19. Montel V, Huang TY, Mose E, et al. Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol 2005; 166: 1565-1579
20. Montel V, Mose ES, Tarin D. Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer 2006; 119: 251-263
21. Urquidi V, Sloan D, Kawai K, et al. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin. Cancer Res 2002; 8: 61-74
22. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750
23. Engstrøm MJ, Opdahl S, Hagen AI, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 2013; 140: 463-473
24. Zhou W, He Z, Xue J, et al. Molecular subtype classification is a determinant of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes. PLoS One 2012; 7: e35881
25. Park D, Kåresen R, Noren T, et al. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch 2007; 451: 11-18
26. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374
27. Castaneda CA, Andrés E, Barcena C, et al. Behaviour of breast cancer molecular subtypes through tumour progression. Clin Transl Oncol 2012; 14: 481-485
28. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA 2006; 295: 2492-2502
29. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey indigenous African women reveal over-representation of triple-negative breast cancer. J Clin Oncol 2009; 27: 4515-4521.